awmsg logo



adalimumab (Humira®)


Reference No. 1793

Publication date:
23/01/2013


Appraisal information

adalimumab (Humira®) 40 mg solution for injection
adalimumab (Humira®) 40 mg/8 ml solution for injection


Company: AbbVie Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 16/01/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, adalimumab (Humira®) cannot be endorsed for use within NHS Wales for the of treatment of moderately active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.
Statement of Advice (SOA)
Download